DelveInsight’s, “Cachexia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Cachexia Understanding
    Cachexia: Overview
    Cachexia is a “wasting” disorder that causes extreme weight loss and muscle wasting, and can include loss of body fat. It is a symptom of many chronic conditions, such as cancer, chronic renal failure, HIV, and multiple sclerosis. The main symptoms of the conditions are severe weight loss, including loss of fat and muscle mass, loss of appetite, anemia (low red blood cells), weakness and fatigue. Cachexia adversely affects the patients’ ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. The goal of treatment for cachexia is to improve symptoms and quality of life. Current therapy for cachexia includes: appetite stimulants such as megestrol acetate drugs, medications that decrease inflammation, diet changes, nutritional supplements and exercise.

    "Cachexia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cachexia pipeline landscape is provided which includes the disease overview and Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.

    Cachexia Emerging Drugs Chapters
    This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Cachexia Emerging Drugs
    • GCWB 204: Green Cross Wellbeing
    GCWB 204 (BST 204), a purified ginseng extract with reinforced ginsenosides Rh2 and Rg3. Green Cross Wellbeing is developing the drug as oral capsule in Phase II clinical studies for the treatment of cancer cachexia.
    • Ponsegromab: Pfizer
    Ponsegromab (formerly PF-06946860) is subcutaneous, monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1). The drug is in Phase I clinical developmental studies for the treatment of Cachexia.
    Further product details are provided in the report??..

    Cachexia: Therapeutic Assessment
    This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Cachexia
    There are approx. 22+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the most advanced stage, i.e. Phase II include, Green Cross Wellbeing.
    • Phases
    DelveInsight’s report covers around 22+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • Intravitreal
    • Subretinal
    • Topical
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Cachexia: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.

    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.

    Cachexia Report Insights
    • Cachexia Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Cachexia Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Cachexia drugs?
    • How many Cachexia drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?
    • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Cachexia and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Incyte Corporation
    • Green Cross Wellbeing
    • AEterna Zentaris
    • AVEO Oncology
    • AstraZeneca
    • Endevica Bio
    • Actimed Therapeutics
    • Creative Medical Technology Holdings
    • Ildong Pharmaceutical
    • Immuneering

    Key Products
    • Ruxolitinib
    • GCWB 204
    • Macimorelin
    • AV 380
    • ART 2713
    • TCMCB-07
    • ACM-002
    • Research programme: amniotic stem cell therapies
    • ID 11917
    • Research programme: cancer therapeutics